v3.26.1
Business Combinations - Additional Information (Details)
€ / shares in Units, € in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2025
EUR (€)
€ / shares
shares
Dec. 31, 2025
EUR (€)
$ / shares
shares
Jan. 31, 2025
EUR (€)
Dec. 31, 2025
EUR (€)
shares
Dec. 18, 2025
Dec. 03, 2025
Nov. 13, 2024
Disclosure of detailed information about business combination [line items]              
Goodwill recognised as of acquisition date     € 6.9        
Biotheus Inc.,              
Disclosure of detailed information about business combination [line items]              
Percentage of voting equity interests acquired (as a percent)             100.00%
Cash paid (fractional shares)     767.8        
Contingent consideration recognised as of acquisition date     79.6        
Equity-settled share-based payment transactions, fair value at grant date     € 49.2        
Vesting period of share-based payment arrangement     4 years        
Settlement of pre-existing relationships     € 565.1        
Intangible assets     172.8        
Bargain from the acquisition     (15.0)        
Revenue of acquiree if combination occurred at beginning of period       € 8.4      
Profit (loss) of acquiree if combination occurred at beginning of period       € 61.8      
Fair value of shares transferred     847.4        
Effects in connection with pre-existing relationships     (567.3)        
Biotheus Inc., | Rights and Other Clinical Pipeline Candidates              
Disclosure of detailed information about business combination [line items]              
Intangible assets     167.7        
Biotheus Inc., | Maximum              
Disclosure of detailed information about business combination [line items]              
Contingent consideration recognised as of acquisition date     144.3        
CureVac              
Disclosure of detailed information about business combination [line items]              
Percentage of voting equity interests acquired (as a percent) 100.00% 100.00%   100.00% 86.75% 81.74%  
Cash paid (fractional shares) € 0.1 € 0.1   € 0.1      
Intangible assets 240.3 240.3   240.3      
Goodwill recognised as of acquisition date (10.6) € (10.6)   € (10.6)      
Revenue of acquiree if combination occurred at beginning of period 2,915.6            
Profit (loss) of acquiree if combination occurred at beginning of period € (1,329.1)            
Shares issued (in shares) 12,075,629 12,075,629   12,075,629   184,071,410  
Fair value of shares transferred € 1,001.1 € 1,001.1   € 1,001.1      
Exchange Ratio In Business Combination 0.05363 0.05363   0.05363      
Weighted average share price (in euros per share) | (per share) € 82.90 € 96.73          
Exchange Rate Used To Determine Fair Value In Business Combination 0.86 0.86   0.86      
Shares issued (in shares) | shares 10,475,287 10,475,287   10,475,287      
thereof fair value of shares from first and second offer period transferred € 868.4 € 868.4   € 868.4      
thereof fair value of shares for the back-end measures 132.7 132.7   132.7      
Effects in connection with pre-existing relationships (600.3) (600.3)   (600.3)      
Settlement Of Contractual Pre-Existing Relationships 488.9 488.9   488.9      
Settlement Of Non-Contractual Pre-Existing Relationships 111.4 111.4   111.4      
Deferred tax liabilities recognised as of acquisition date € 13.8 € 13.8   € 13.8      
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination     9.6        
Transaction costs     7.6        
Issue costs of equity instruments for business combination     € 2.0